Table 2.
Clinical Characteristics and Laboratory Data of Patients With cGvHD With and Without Vitiligo and/or Alopecia Areataa
| Characteristic | Total (n = 282) | No Vitiligo or AA (n = 267) | Vitiligo and/or AA (n = 15) | P Value |
|---|---|---|---|---|
| Age, median (range), y | 46 (4–70) | 46 (4–70) | 38 (9–69) | .30 |
| ≤18 y | 20/282 (7.09) | 17/267 (6.37) | 3/15 (20.00) | … |
| Sex | ||||
| Male | 160/282 (56.73) | 150/267 (56.18) | 10/15 (66.67) | .59 |
| Female | 122/282 (43.26) | 117/267 (43.82) | 5/15 (33.33) | |
| Primary disease | ||||
| ALL/AML/MDS | 128/282 (45.39) | 123/267 (46.07) | 5/15 (33.33) | .22 |
| CML | 39/282 (13.82) | 34/267 (12.73) | 5/15 (33.33) | |
| CLL | 17/282 (6.03) | 16/267 (5.99) | 1/15 (6.67) | |
| Malignant lymphoma | 64/282 (22.69) | 62/267 (23.22) | 2/15 (13.33) | |
| Otherb | 34/282 (12.06) | 32/267 (11.99) | 215 (13.33) | |
| Conditioning regimen | ||||
| TBI−/MAC− | 100/279 (35.84) | 94/265 (35.47) | 6/14 (42.86) | .93 |
| TBI+/MAC− | 24/279 (8.60) | 23/265 (8.68) | 1/14 (7.14) | |
| TBI−/MAC+ | 74/279 (26.52) | 70/265 (26.42) | 4/14 (28.57) | |
| TBI+/MAC+ | 81/279 (29.03) | 78/265 (29.43) | 3/14 (21.43) | |
| MAC | 155/279 (55.56) | 148/265 (55.85) | 7/14 (50.00) | .78 |
| RIC | 124/279 (44.44) | 117/265 (44.15) | 7/14 (50.00) | … |
| TBI | 105/279 (37.63) | 101/265 (38.11) | 4/14 (28.57) | .58 |
| DLI post transplant | ||||
| Yes | 25/262 (9.54) | 24/247 (9.72) | 1/15 (6.67) | >.99 |
| No | 247/262 (94.27) | 223/247 (9.28) | 14/15 (93.33) | |
| Stem cell source | .05 | |||
| BM | 53/282 (18.79) | 49/267 (18.35) | 4/15 (26.67) | .49 |
| PB | 219/282 (77.66) | 210/267 (78.65) | 9/15 (60.00) | .11 |
| Cord | 10/282 (3.55) | 8/267 (3.00) | 2/15 (13.33) | .09 |
| Donor relationship | ||||
| Related | 174/281 (61.92) | 163/266 (61.28) | 11/15 (73.33) | .42 |
| Unrelated | 107/281 (38.08) | 103/266 (38.72) | 4/15 (26.67) | |
| HLA matched | ||||
| Yes | 230/275 (83.64) | 217/260 (83.46) | 13/15 (86.67) | >.99 |
| No | 45/275 (16.36) | 43/260 (16.54) | 2/15 (13.33) | |
| Donor sex | ||||
| Male | 135/255 (52.94) | 135/241 (56.02) | 0/14 | <.001 |
| Female | 120/255 (47.06) | 106/241 (43.98) | 14/14 (100) | |
| Donor to patient sex match or mismatch | <.001 | |||
| M to M | 76/256 (30.08) | 76/242 (31.82) | 0/14 | … |
| F to F | 57/256 (21.88) | 52/242 (21.07) | 5/14 (35.71) | … |
| M to F | 55/256 (21.88) | 55/242 (22.73) | 0/14 | .05 |
| F to M | 68/256 (26.17) | 59/242 (24.38) | 9/14 (64.29) | .003 |
| cGvHD duration, y | ||||
| ≤1 | 79/282 (28.01) | 76/267 (28.46) | 3/15 (20.00) | .57 |
| ≥1 | 203/282 (71.99) | 191/267 (71.54) | 12/15 (80.00) | |
| cGvHD onset | ||||
| Quiescent | 77/280 (27.50) | 75/265 (28.30) | 2/15 (13.33) | .31 |
| De novo | 92/280 (32.86) | 88/265 (33.21) | 4/15 (26.67) | |
| Progressive | 111/280 (39.64) | 102/265 (38.49) | 9/15 (60.00) | |
| Intensity of immunosuppressionc | ||||
| None or mild | 70/281 (24.91) | 66/266 (24.81) | 4/15 (26.67) | >.99 |
| Moderate | 100/281 (35.59) | 95/266 (35.71) | 5/15 (33.33) | |
| High | 111/281 (39.5) | 105/266 (39.47) | 6/15 (40.00) | |
| Presence of skin cGvHDd | ||||
| Yes | 215/281 (76.51) | 202 (75.70) | 13/15 (86.67) | .53 |
| No | 66/281 (23.49) | 64/266 (24.06) | 2/15 (13.33) | |
| Median BSA, % | ||||
| Erythema | 0.81 | 0.86 | 0.54 | .96 |
| Sclerosis | 0 | 2.16 | 0.36 | .81 |
| NIH Global Severity score | ||||
| Moderate | 81/278 (29.14) | 74/264 (71.97) | 7/14 (50.00) | .13 |
| Severe | 197/278 (70.86) | 190/264 (71.97) | 7/14 (50.00) | |
| Laboratory parameters | ||||
| Presence of autoantibodies | 133/279 (47.67) | 124/264 (46.97) | 9/15 (60.00) | .43 |
| ANA | 90/278 (32.37) | 85/264 (32.20) | 5/14 (35.71) | .78 |
| RF | 35/275 (12.73) | 31/260 (11.92) | 4/15 (26.67) | .11 |
| Anti-CCP | 20/277 (7.22) | 18/262 (6.87) | 2/15 (13.33) | .30 |
| Antiparietal | 7/277 (2.53) | 5/262 (1.91) | 2/15 (13.33) | .05 |
| Anticentromere | 9/277 (3.25) | 8/262 (3.05) | 1/15 (6.67) | .40 |
| Anti-RNP | 14/279 (5.02) | 12/264 (4.55) | 2/15 (13.33) | .17 |
| Anti-smith | 3/279 (1.08) | 2/264 (0.76) | 1/15 (6.67) | .15 |
| ACAIgM | 22/277 (7.94) | 21/262 (8.02) | 1/15 (6.67) | >.99 |
| ACAIgG | 23/277 (8.30) | 19/262 (7.25) | 4/15 (26.67) | .03 |
| Anti-ENA | 23/279 (8.24) | 21/264 (7.95) | 2/15 (13.33) | .36 |
| Anti-TPO | 3/59 (5.08) | 2/51 (3.92) | 1/8 (12.50) | .36 |
| Low CD3 (<1000/UL) | 156/261 (59.77) | 149/247 (60.32) | 7/14 (50.00) | .58 |
| Low CD4 (<250/UL) | 80/263 (30.42) | 77/249 (30.92) | 3/14 (21.43) | .56 |
| Low CD19 (<400/UL) | 199/282 (70.57) | 192/267 (71.91) | 7/15 (46.67) | .05 |
| High IgG (>1200 mg/dL) | 46/278 (16.55) | 41/263 (15.59) | 5/15 (33.33) | .02e |
Abbreviations: AA, alopecia areata; ALL, acute lymphoblastic leukemia; AML, acute myelogenous leukemia; ANA, antinuclear antibody; BM, bone marrow; BSA, body surface area; CCP, cyclic citrullinated peptides; cGvHD, chronic graft-vs-host disease; CLL, chronic lymphocytic leukemia; CML, chronic myelogenous leukemia; DLI, donor lymphocyte infusion; ENA, extractable nuclear antigens; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; NIH, National Institutes of Health; PB, peripheral blood; RIC, reduced-intensity conditioning; RF, rheumatoid factor; RNP, ribonucleoprotein; TBI, total body irradiation; TPO, thyroid peroxidase; …, analysis not performed.
Unless otherwise indicated, data are reported as number of participants/total number in the category (percentage).
The “other” category includes patients with multiple myeloma, sarcoma, immunodeficiency, aplastic anemia and/or paroxysmal nocturnal hemoglobinuria, and nonmalignant diseases.
Mild immunosuppression defined as single-agent prednisone at less than 0.5 mg/kg/d; moderate, prednisone at 0.5 mg/kg/d or higher and/or any other single agent or modality; high, 2 or more agents or modalities with or without prednisone at 0.5 mg/kg/d.
Indicates both sclerotic and/or nonsclerotic dermatologic manifestations of cGvHD.
P value relates to the comparison across low vs normal vs high IgG.